PPIs and Clopidogrel: Do We Have to Worry?

Kuritzky, Louis
November 2009
Internal Medicine Alert;11/15/2009, Vol. 31 Issue 21, p167
Product Review
The article evaluates the Proton pump inhibitors (PPIs) and clopidogrel.


Related Articles

  • Esomeprazole. Spencer, C.M.; Faulds, D. // Drugs;Aug2000, Vol. 60 Issue 2, p321 

    â–´ Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer. â–´ Esomeprazole provided better control of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted in patients with...

  • What's behind the link between PPIs, clopidogrel and CV events?  // Reactions Weekly;2/4/2012, Issue 1387, p3 

    The article reports on a research study which showed the use of a proton pump inhibitor (PPI) to be independently associated with a higher rate of cardiovascular (CV) events among patients with acute coronary syndromes (ACS) receiving clopidogrel.

  • Shift to PPIs fuels antacid gains.  // Chain Drug Review;10/12/2015, Vol. 37 Issue 16, p15 

    The article reports on the steady sales growth of proton pump inhibitors (PPIs) and antacids in the U.S. in 2015 and mentions the trend's association to the high number of Americans that experienced heartburn.

  • Rabeprazole: A Viewpoint by Noriaki Takeguchi. Takeguchi, N. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action of the medication; Characteristics as a proton pump inhibitor.

  • Rabeprazole: A Viewpoint by Simmy Bank. Bank, S. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action; Characteristics as a proton pump inhibitor; Results of clinical trials on the medication.

  • Clinical Pharmacology of Proton Pump Inhibitors: What the Practising Physician Needs to Know. Robinson, Malcolm; Horn, John // Drugs;2003, Vol. 63 Issue 24, p2739 

    Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump,...

  • Proton Pump Inhibitors.  // Current Medical Literature: Gastroenterology;2008, Vol. 27 Issue 4, p120 

    The article presents abstracts of research on proton pump inhibitors (PPI) including the "Addition of H2 Receptor Antagonist to PPI in Improving Acid Control and Decreases Nocturnal Acid Breakthrough," and "Predictable Prolonged Suppression of Gastric Acidity With a Novel Proton Pump Inhibitor,...

  • Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia. Sarkar, Monika; Hennessy, Sean; Yu-Xiao Yang // Annals of Internal Medicine;9/16/2008, Vol. 149 Issue 6, p391 

    Background: Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). Objective: To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. Design: Nested case-control study....

  • Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. Ramsay, Emmae N.; Pratt, Nicole L.; Ryan, Philip; Roughead, Elizabeth E. // BMC Medical Research Methodology;2013, Vol. 13 Issue 1, p1 

    Background: To compare the results of a new-user cohort study design and the self-controlled case series (SCCS) design using the risk of hospitalisation for pneumonia in those dispensed proton pump inhibitors compared to those unexposed as a case study. Methods: The Australian Government...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics